Bio-Rad Laboratories (BIO) Cost of Revenue (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Cost of Revenue data on file, last reported at $282.7 million in Q1 2026.

• Quarterly Cost of Revenue rose 1.18% year-over-year to $282.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 5.45% YoY) and the FY2025 annual result came in at $1.2 billion, up 4.69% from the prior year.
• Cost of Revenue slipped to $282.7 million in Q1 2026 per BIO's latest filing, from $348.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $348.0 million in Q4 2025 and bottomed at $279.4 million in Q1 2025.
• The 5-year median for Cost of Revenue is $306.3 million (2025), against an average of $305.5 million.
• The widest annual swing landed in 2024, when Cost of Revenue dropped 11.06%; it then grew 8.08% in 2025.
• Tracing BIO's Cost of Revenue over 5 years: stood at $333.2 million in 2022, then slipped by 5.51% to $314.8 million in 2023, then rose by 3.43% to $325.6 million in 2024, then climbed by 6.88% to $348.0 million in 2025, then decreased by 18.76% to $282.7 million in 2026.
• Per Business Quant, the three latest BIO Cost of Revenue figures stand at $282.7 million (Q1 2026), $348.0 million (Q4 2025), and $309.6 million (Q3 2025).

Peer Comparison